日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Quemliclustat联合化疗(加或不加zimberelimab)治疗转移性胰腺腺癌:一项随机1期试验

Wainberg, Zev A; Manji, Gulam A; Bahary, Nathan; Ulahannan, Susanna V; Pant, Shubham; Spigel, David R; Uboha, Nataliya V; Oberstein, Paul E; Saeed, Anwaar; Beagle, Brandon; Kim, Ji Yun; Wang, Ning; Weeder, Ben; Shitole, Shravani; Mrouj, Karim; Scott, Jennifer R; Ensign, Lisa G; DiRenzo, Daniel M; Walters, Matthew J; Wu, Wilson; Kaplan, Angelo; Cho, Soonweng; Kabbarah, Omar; O'Reilly, Eileen M

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group

将循环肿瘤DNA检测纳入临床试验:美国国家癌症研究所胃肠肿瘤循环肿瘤DNA工作组的立场文件

Rajdev, Lakshmi; King, Gentry G; Lieu, Christopher H; Cohen, Stacey A; Pant, Shubham; Uboha, Nataliya V; Deming, Dustin; Malla, Midhun; Kasi, Anup; Klute, Kelsey; Spencer, Kristen R; Dasari, Arvind; Morris, Van K; Botta, Gregory; Lowy, Andrew M; O'Hara, Mark H; Eads, Jennifer; King, Daniel; Shah, Manish A; Hong, Theodore S; Parikh, Aparna; Klempner, Samuel J; Jabbour, Salma K; Chawla, Akhil; Molena, Daniela; George, Thomas J; Gibson, Michael K; Allegra, Carmen; Goodman, Karyn; Eng, Cathy; Philip, Philip A

Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity.

利用亚克隆反应异质性来定义癌症类器官的治疗敏感性

Kratz Jeremy D, Rehman Shujah, Johnson Katherine A, Gillette Amani A, Sunil Aishwarya, Favreau Peter F, Pasch Cheri A, Miller Devon, Zarling Lucas C, Yeung Austin H, Clipson Linda, Anderson Samantha J, Steimle Alyssa K, Sprackling Carley M, Lemmon Kayla K, Abbott Daniel E, Burkard Mark E, Bassetti Michael F, Eickhoff Jens C, Foley Eugene F, Heise Charles P, Kimple Randall J, Lawson Elise H, LoConte Noelle K, Lubner Sam J, Mulkerin Daniel L, Matkowskyj Kristina A, Sanger Cristina B, Uboha Nataliya V, Mcilwain Sean J, Ong Irene M, Carchman Evie H, Skala Melissa C, Deming Dustin A

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

ATR抑制剂Elimusertib联合顺铂治疗晚期实体瘤患者:加州癌症联盟I期试验(NCI 10404)

Parikh, Mamta; Uboha, Nataliya V; Takebe, Naoko; Tam, Kit; Bedard, Philippe L; Wisinski, Kari B; Mittra, Arjun; Yin, Ming; Yang, Yuanquan; Noonan, Anne M; Holleran, Julianne L; Ruel, Christopher; Frankel, Paul; Beumer, Jan H; Newman, Edward M; Danilov, Alexey V; Gore, Steven D; Lara, Primo N Jr

Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer

围手术期阿维鲁单抗联合放化疗治疗II/III期可切除食管癌和胃食管交界癌的I/II期临床试验

Uboha, Nataliya V; Basree, Mustafa M; Eickhoff, Jens C; Deming, Dustin A; Matkowskyj, Kristina; Maloney, James; McCarthy, Daniel; DeCamp, Malcolm; LoConte, Noelle; Emmerich, Philip B; Kraus, Sean; Patel, Monica A; Kratz, Jeremy D; Lubner, Sam J; Hurst, Newton; Bassetti, Michael F

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer

阿达格拉西布联合西妥昔单抗治疗KRASG12C突变转移性结直肠癌患者的疗效和安全性

Yaeger, Rona; Uboha, Nataliya V; Pelster, Meredith S; Bekaii-Saab, Tanios S; Barve, Minal; Saltzman, Joel; Sabari, Joshua K; Peguero, Julio A; Paulson, Andrew Scott; Jänne, Pasi A; Cruz-Correa, Marcia; Anderes, Kenna; Velastegui, Karen; Yan, Xiaohong; Der-Torossian, Hirak; Klempner, Samuel J; Kopetz, Scott E

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

一项针对转移性胰腺导管腺癌患者的Ib/II期随机临床试验,评估奥莱克鲁单抗联合或不联合度伐利尤单抗及化疗的疗效

Coveler, Andrew L; Reilley, Matthew J; Zalupski, Mark; Macarulla, Teresa; Fountzilas, Christos; Ponz-Sarvisé, Mariano; Nagrial, Adnan; Uboha, Nataliya V; Frentzas, Sophia; Overman, Michael; Noonan, Anne; Messersmith, Wells A; Pavlakis, Nick; Mettu, Niharika B; Bisha, Ina; Wang, Ying; Smith, Paul; Murtomaki, Elina; Bielska, Agata A; Bragulat, Veronique; Cooper, Zachary A; Kumar, Rakesh; Spigel, David R

Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial

FUZE多中心、开放标签、II期篮式试验评估Debio 1347在FGFR融合阳性晚期实体瘤患者中的疗效

Grivas, Petros; Garralda, Elena; Meric-Bernstam, Funda; Mellinghoff, Ingo K; Goyal, Lipika; Harding, James J; Dees, E Claire; Bahleda, Rastislav; Azad, Nilofer S; Karippot, Asha; Kurzrock, Razelle; Tabernero, Josep; Kononen, Juha; Ng, Matthew C H; Mehta, Rutika; Uboha, Nataliya V; Bigot, Frédéric; Boni, Valentina; Bowyer, Samantha E; Breder, Valeriy; Cervantes, Andrés; Chan, Nancy; Cleary, James M; Dhawan, Mallika; Eefsen, Rikke L; Ewing, James; Graham, Donna M; Guren, Tormod K; Won Kim, Jin; Koynov, Krassimir; Oh, Do-Youn; Redman, Rebecca; Yen, Chia-Jui; Spetzler, David; Roubaudi-Fraschini, Marie-Claude; Nicolas-Metral, Valerie; Ait-Sarkouh, Rafik; Zanna, Claudio; Ennaji, Abdallah; Pokorska-Bocci, Anna; Flaherty, Keith T

A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Big Ten Cancer Research Consortium trial

一项评估FOLFOX联合白蛋白紫杉醇治疗转移性或晚期不可切除胃癌、胃食管交界处腺癌的II期临床研究:一项由十大癌症研究联盟开展的试验

Dreyer, Marie S; Mulcahy, Mary; Kocherginsky, Masha; Chen, Yolande; Hochster, Howard S; Kasi, Pashtoon M; Kircher, Sheetal; Lou, Emil; Ma, Yangruijue; Uboha, Nataliya V; Benson, Al B 3rd

Precision of liver and pancreas apparent diffusion coefficients using motion-compensated gradient waveforms in DWI

利用运动补偿梯度波形在DWI中测量肝脏和胰腺表观扩散系数的精度

Starekova, Jitka; Geng, Ruiqi; Wang, Zihan; Zhang, Yuxin; Uboha, Nataliya V; Pirasteh, Ali; Hernando, Diego